Investor Update

16 November 2021

Invitation to Roche’s virtual event on key hematology data presented at ASH 2021


We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 15 December, 2021, highlighting Roche data presented at the virtual American Society of Hematology (ASH) 63rd Annual Meeting, from 11-14th December.

16:00 – 17:30 CET / 15:00 - 16:30 GMT
10:00 – 11:30 am EST / 7:00 – 8:30 am PST

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers).


Karl Mahler, Head of Investor Relations

Hematology franchise overview
Peter Ahnesorg, Franchise Head Hematology

Review of key clinical data presented at ASH: Hemlibra, mosun, glofit, cevostamab
Charles Fuchs, Senior Vice President - Global Head Of Oncology And Hematology Product Development

Presentation of POLARIX data
Franck Morschhauser, MD, PhD, Professor of Hematology, University of Lille; President of LYSA, LYSARC


 The slides will be available for download at 15:00 CET on the day of the event. click here

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to

A replay of the webcast will be available via

*privacy notice

Best regards,

Karl Mahler
Head of Investor Relations


Loren Kalm
Head of Investor Relations, North America

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503

Dr. Sabine Borngräber
Phone: +41 61 68-88027

Dr. Bruno Eschli
Phone: +41 61 68-75284
Dr. Birgit Masjost
Phone: +41 61 68-84814
Dr. Gerard Tobin
Phone: +41 61 68-72942
Jon Kaspar Bayard
Phone: +41 61 68-83894
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217